Pencil Beam Proton Therapy for Recurrences in Anal Cancer Patients Previously Treated With Radiotherapy (DACG 5)

Launched by UNIVERSITY OF AARHUS · Sep 14, 2021

Keywords

ClinConnect Summary

This clinical trial, called DACG 5, is studying a new treatment approach for patients who have recurring anal cancer after previously receiving radiation therapy. The researchers want to see how effective and safe a type of radiation called pencil beam proton therapy is when given a higher dose. This treatment is being tested for patients who have tumors that are hard to remove through surgery or for those who choose not to have surgery. The goal is to control the cancer better while keeping side effects manageable.

To participate in this trial, patients need to have confirmed recurrent anal cancer and must have had prior radiation treatment. They should be over 18 years old, have good overall health, and be able to provide written consent to join. Participants will receive tailored radiation treatment and will be closely monitored throughout the process. It's important to note that patients with cancer that has spread to other parts of the body or those who cannot manage the treatment process may not be eligible. This trial is currently recruiting participants, and it's a valuable opportunity to explore a promising new therapy for recurrent anal cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Recurrent anal cancer
• • Bioptically verified (squamous cell carcinoma)
• • Available dose plan from primary radiotherapy
• • Previous RT (\>30Gy EQD2)
• • Evaluated in MDT-conferences (Herlev, Aarhus)
• • Age\>18 years
• • PS 0-2
• • Adequate organ function
• • Written informed consent
• Exclusion Criteria:
• • Distant metastases deemed without curative intended treatment options (PET-CT)
• • Unable to undergo MRI, PET-CT
• • Inability to attend full course radiotherapy and follow up in the outpatient clinic.